Seeking Alpha

Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have...

Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have more room to run, or so says Needham's Chad Messer who ups his price target to $100 from $50. "Assuming just 17% of [an] estimated 14K eligible patients are on treatment by 2018, we forecast worldwide Juxtapid sales of $590M, equating to AEGR EPS of $7.28," Messer notes. Slap a 30x multiple on that (which Messer justifies as "conservative" by referring to peers' multiples), apply a 25% discount, and you have yourself a $100 12-month PT.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|